-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
HUTCHMED (NASDAQ:HCM) Sees Unusually-High Trading Volume
HUTCHMED (NASDAQ:HCM) Sees Unusually-High Trading Volume
HUTCHMED (China) Limited (NASDAQ:HCM – Get Rating) saw strong trading volume on Friday . 13,322 shares changed hands during mid-day trading, a decline of 92% from the previous session's volume of 166,753 shares.The stock last traded at $13.89 and had previously closed at $13.14.
Analyst Upgrades and Downgrades
A number of equities analysts have recently commented on the company. The Goldman Sachs Group lifted their target price on HUTCHMED from $14.00 to $16.00 and gave the stock a "neutral" rating in a report on Tuesday, August 9th. StockNews.com upgraded HUTCHMED from a "sell" rating to a "hold" rating in a report on Monday, August 1st.
Get HUTCHMED alerts:HUTCHMED Stock Up 6.3 %
The stock has a fifty day moving average price of $13.18 and a 200 day moving average price of $14.40.
Institutional Investors Weigh In On HUTCHMED
A number of institutional investors and hedge funds have recently modified their holdings of HCM. Quantbot Technologies LP bought a new stake in shares of HUTCHMED during the 1st quarter worth approximately $44,000. US Bancorp DE lifted its stake in shares of HUTCHMED by 270.9% during the 1st quarter. US Bancorp DE now owns 3,687 shares of the company's stock worth $70,000 after acquiring an additional 2,693 shares during the last quarter. National Pension Service lifted its stake in shares of HUTCHMED by 429.1% during the 2nd quarter. National Pension Service now owns 9,101 shares of the company's stock worth $115,000 after acquiring an additional 7,381 shares during the last quarter. abrdn plc bought a new stake in shares of HUTCHMED during the 2nd quarter worth approximately $133,000. Finally, Jane Street Group LLC bought a new stake in HUTCHMED during the 2nd quarter valued at $160,000. 27.37% of the stock is owned by institutional investors.HUTCHMED Company Profile
(Get Rating)
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors.
Featured Articles
- Get a free copy of the StockNews.com research report on HUTCHMED (HCM)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with MarketBeat.com's FREE daily email newsletter.
HUTCHMED (China) Limited (NASDAQ:HCM – Get Rating) saw strong trading volume on Friday . 13,322 shares changed hands during mid-day trading, a decline of 92% from the previous session's volume of 166,753 shares.The stock last traded at $13.89 and had previously closed at $13.14.
和黃醫藥(中國)有限公司(納斯達克：HCM-GET評級)週五成交量強勁。午盤交易中，13,322股股票易手，較前一交易日166,753股下跌92%。該股尾盤報13.89美元，此前收盤報13.14美元。
Analyst Upgrades and Downgrades
分析師升級和下調評級
A number of equities analysts have recently commented on the company. The Goldman Sachs Group lifted their target price on HUTCHMED from $14.00 to $16.00 and gave the stock a "neutral" rating in a report on Tuesday, August 9th. StockNews.com upgraded HUTCHMED from a "sell" rating to a "hold" rating in a report on Monday, August 1st.
一些股票分析師最近對該公司發表了評論。8月9日，在週二的一份報告中，高盛將和黃醫藥的目標價從14.00美元上調至16.00美元，並給予該股“中性”評級。在8月1日週一的一篇報道中，斯托克新聞網將和黃醫藥的評級從賣出上調至持有。
HUTCHMED Stock Up 6.3 %
和黃醫藥股價上漲6.3%
The stock has a fifty day moving average price of $13.18 and a 200 day moving average price of $14.40.
該股的50日移動均價為13.18美元，200日移動均價為14.40美元。
Institutional Investors Weigh In On HUTCHMED
機構投資者看好和黃醫藥
HUTCHMED Company Profile
和黃醫藥公司簡介
(Get Rating)
(獲取評級)
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors.
和黃醫藥(中國)有限公司在香港和國際上發現、開發癌症和免疫疾病的靶向療法和免疫療法，並將其商業化。它在腫瘤學/免疫學和其他風險投資領域開展業務。該公司開發Savolitinib，一種治療非小細胞肺癌(NSCLC)、乳頭狀細胞癌和腎癌、結直腸癌(CRC)和胃癌(GC)的抑制劑；以及Fruquintinib，一種治療CRC、乳腺癌、GC、子宮內膜癌(EMC)、非小細胞肺癌、肝細胞癌以及胃腸道和實體腫瘤的抑制劑。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on HUTCHMED (HCM)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- 免費獲取斯托克新聞網關於和黃醫藥的研究報告
- MarketBeat：回顧一週9/5-9/9
- 為網絡安全股創紀錄的季度做準備
- 汽車市場正在緩慢復甦，這些股票可能表現優異
- DocuSign是否即將發生重大逆轉？
- 石油和天然氣股票：投資可再生能源的安全途徑
Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with MarketBeat.com's FREE daily email newsletter.
接受《和黃醫藥日報》的新聞和評級-在下面輸入您的電子郵件地址，即可通過MarketBeat.com的免費每日電子郵件時事通訊接收對和黃醫藥及相關公司的最新新聞和分析師評級的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧